MA-EDB
9.12.2021 15:02:04 CET | Business Wire | Press release
EDB , an open source innovator and the leading contributor to PostgreSQL®, announced today the worldwide immediate availability of EDB 14, its premiere PostgreSQL platform. EDB® 14 adds critical enterprise capabilities, including extreme high availability and multi-master replication, which are necessary for running today’s mission-critical applications, whether high-speed transactional systems in financial services or geo-distributed analytical systems in retail. Further improvements to EDB’s powerful Oracle database compatibility technology enable even smoother migration, which is essential for the growing number of organizations moving to the cloud.
“Postgres is the fastest growing database platform worldwide with rapid adoption by developers and enterprises," Marc Linster, CTO, EDB. "With EDB 14, we've pushed Postgres even further to support our customers’ most demanding workloads and help them migrate faster at a lower total cost of ownership. This release offers even more incentive for businesses to move away from traditional databases and get onto Postgres now, or get more from it if they’re already there."
EDB 14 highlights
With the largest team of PostgreSQL engineers of any other software vendor, EDB continues to strengthen PostgreSQL to help enterprises do more and go faster. Highlights include:
- Extreme high availability : Postgres-BDR®, a component of the EDB 14 release, allows customers to run PostgreSQL with 99.999% availability through its innovative multi-master replication capability, a feature no other PostgreSQL database offers. Multi-master replication allows customers to operate their PostgreSQL databases in “Always On” architectures with zero downtime updates and upgrades, which is critical for keeping their databases running optimally and securely.
- Enhanced Oracle database compatibility : EDB Postgres Advanced ServerTM adds features that further improve compatibility with Oracle database technology. This capability is vital for customers looking to move applications or data from Oracle database to PostgreSQL and benefit from its superior usability and reduced operational and licensing costs.
- Improved DevOps for PostgreSQL : EDB’s Cloud Native PostgreSQL, another component of EDB 14, helps Kubernetes users take full advantage of PostgreSQL as their database of choice. This latest version of Cloud Native PostgreSQL provides connection pooling to enable workloads with many concurrent connections to run in Kubernetes, supporting applications with even higher user demands than before.
- Deployment flexibility : PostgreSQL customers can deploy EDB 14 in any manner, including using EDB’s BigAnimalTM , the first fully managed PostgreSQL database in the cloud with compatibility for Oracle database technology, or self-manage their database on premises.
- Choice of PostgreSQL distributions : The EDB 14 platform has been tested with PostgreSQL 14 and EDB Postgres Advanced Server 14, enabling customers to choose between PostgreSQL distributions and tools, including open source, EDB, or a combination.
To learn more about EDB 14, visit the EDB blog . For details about BigAnimal and to sign up for a free trial, visit www.BigAnimal.com .
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com .
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres is a trademark of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
Oracle, Java, and MySQL are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005194/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
